This marks the final regulatory step for the drug’s upcoming commercialization in Italy, confirming Oncopeptides’ expectation of first sales during H1, 2025, describes the company in a press release.

The company’s goal is to make the treatment available to eligible Italian patients with relapsed and refractory multiple myeloma over the coming months, it states.

“We are now ready to start making Pepaxti accessible to patients who urgently need new and innovative treatment options, and we expect to commence launch activities during the first quarter,” says Bruno Bolognese, Country Manager Italy and European Head of Medical Affairs at Oncopeptides. “Italy represents a key market for Oncopeptides, with its large patient population and extensive clinical experience with Pepaxti.”

Oncopeptides is currently in the process of strengthening its presence in Italy by expanding its team and investing in initiatives to raise awareness about Pepaxti and its benefits.